By Sheeba M. | Weedstock Market Intelligence | Monday, September 28, 2026 — 2:00 PM ET
With four business days remaining before the October 2, 2026 window that cannabis markets have circled on their calendars, investors are entering the most consequential stretch of the rescheduling saga since the DEA’s initial proposal was published in the Federal Register in 2024. Here is what to watch, what the timelines mean, and how the market is pricing the outcome.
Where the DEA Rescheduling Process Stands
The DEA’s proposal to reclassify cannabis from Schedule I to Schedule III under the Controlled Substances Act has cleared the Department of Justice review, the public comment period (which generated over 43,000 submissions — the largest in DEA history), and the administrative law judge (ALJ) evidentiary hearing process. The remaining step is the DEA Administrator’s final order, which becomes effective upon publication in the Federal Register.
Multiple sources tracking the federal rulemaking calendar — including the Office of Information and Regulatory Affairs (OIRA) docket — indicate the final rule is in the “final review” stage, the last administrative checkpoint before signature. Once signed, the rule typically reaches the Federal Register within 7–14 business days. The October 2 window reflects the outer boundary of that timeline from the most recent docket update.
What Schedule III Means in Practice
The most immediate financial impact of rescheduling for publicly traded cannabis companies would be the elimination of the 280E tax provision, which currently disallows standard business deductions for companies “trafficking” in Schedule I or II substances. This creates effective tax rates of 60–80% for many MSOs — a structural disadvantage that has suppressed profitability and free cash flow for years.
Under Schedule III classification:
- 280E no longer applies — MSOs can deduct standard operating expenses, potentially saving $100M–$200M annually across the largest operators (CURLF, GTBIF, VRNOF, AYR)
- Banking access expands — though full SAFE Banking Act protections require Congressional action, Schedule III status removes a key compliance barrier for mid-tier financial institutions
- Capital markets open — U.S.-listed MSOs currently trade on OTC markets; Schedule III reclassification is widely expected to clear the pathway for NYSE/NASDAQ uplisting applications
- Insurance and institutional access improve — investment mandates that prohibit Schedule I exposure would be modified under Schedule III status
Risks Still in Play
Sophisticated investors are not treating rescheduling as a certainty, despite the advanced stage of the process. Three risk vectors remain:
Legal challenge: Prohibitionist advocacy groups have signaled intent to challenge the final rule in federal court, potentially seeking a stay that would delay implementation. Courts could grant a temporary restraining order while litigation proceeds, creating a scenario where the rule is published but not operative.
Congressional interference: A resolution of disapproval under the Congressional Review Act (CRA) could theoretically block the rule if both chambers passed it and the President signed — an outcome considered unlikely given the current political configuration, but technically possible during the 60-day CRA review window.
Implementation lag: Even if the rule takes effect cleanly, the IRS has indicated it would need to issue guidance on 280E applicability transition. Companies may not be able to file amended returns or apply new deduction rules immediately.
Trading the Week
The cannabis sector is pricing in approximately 65–70% probability of a clean rule publication by October 7, based on options-implied move analysis. The market’s reaction function will depend heavily on when the news breaks — pre-market or mid-session announcements tend to produce larger initial moves than after-hours publications.
For investors tracking the broader sector, the DEA Final-4 framework means volatility is not just possible this week — it is structurally embedded in the tape. Position sizing and defined-risk structures (options over direct equity exposure) are the prudent approach for those who need to be in the trade heading into October.
Stay current on cannabis regulatory developments at Weedstock. Track stock movements via the cannabis stock tracker. Nothing in this article constitutes investment advice.